Browse
Submit Data
Databases
API
Help

Dataset Information

4 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Multicenter, Open-Label, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 (PEG-Irinotecan) Versus Irinotecan in Patients with Second-Line, Irinotecan-Naïve, KRAS-Mutant, Colorectal Cancer with Metastatic or Locally Advanced Disease. Estudio de fase II, Aleatorizado, Abierto, Multicéntrico para Evaluar la Eficacia y Seguridad de NKTR-102 (Irinotecán-PEG) Frente a Irinotec...

ABSTRACT: Primary objectives: To estimate the progression-free survival (PFS) with NKTR-102 versus irinotecan. Primary endpoints: The primary endpoint of this study is progression-free survival (PFS), which is defined as the time from the date of randomization to the date of progressive disease (PD), death due to any cause, premature removal from the study due to unacceptable toxicity or the initiation of new therapy.

DISEASE(S): Malignant Solid Tumor,Refractory Solid Tumors (colorectal Cancer) tumores Sólidos Refractarios (cáncer Colorrectal),Colorectal Cancer,Refractory Solid Tumors (colorectal Cancer)tumores Sólidos Refractarios (cáncer Colorrectal)

PROVIDER: 2524788 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.

Project description: Not available

| S-EPMC4236622 | biostudies-literature

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Project description: Not available

| S-EPMC4878105 | biostudies-literature

Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.

Project description: Not available

| S-EPMC4768213 | biostudies-literature

Genome and transcriptome study of the response to irinotecan and bevacizumab in recurrent glioblastomas (CIT - Homo sapiens - BEVA)

Project description:A Cartes d'Identite des Tumeurs (CIT) project from the French National League Against Cancer (http://cit.ligue-cancer.net ) 25 glioblastoma multiforme tumors hybridized on Illumina SNP and Affymetrix gene expression arrays. Project leader : François DUCRAY (francois.ducray@chu-lyon.fr). CIT Analysis : Julien LAFFAIRE (laffairej@ligue-cancer.net). Note: PFS : progression-free survival, OS: Overall Survival,BCNU : Carmustine (chemotherapy agent). RESPONDER: if the patient has shown or not shown a response to the treatment (Bevacizumab (Avastin) plus Irinotecan). Progression during : If the disease has progressed (cancer relapse or patient's death); otherwise (patient is alive without relapse).

2013-01-15 | E-MTAB-951 | biostudies-arrayexpress

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Project description:This study will evaluate whether NKTR-102, an investigational drug has an anti-tumor effect in patients with colorectal cancer. This study will also evaluate how the safety and anti-tumor activity of NKTR-102 compares with irinotecan, a cancer drug that is approved for use in the US for treatment of patients with certain types of colorectal cancer.

| 2068904 | ecrin-mdr-crc

Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR)

Project description:Primary objectives: • Progression-Free Survival (PFS) in patients with low verus high miR-31-5p expression: Compare the predictive value of miR-31-5p expression as measured progression free survival. PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression as assessed according to RECIST 1.1 or death due to any cause. Subjects who die without a reported prior progression will be considered to have progressed on the date of their death. Subjects who did not progress or die will be censored on the date of their last tumor assessment. Subjects who started any subsequent anti-cancer therapy without a prior reported progression will be censored. Primary endpoints: PFS A vs PFS B (PFS A > PFS B with ≥ 25 %)

| 2538002 | ecrin-mdr-crc

A phase II study of guadecitabien combined with irinotecan vs regorafenib or TAS-102 in previously treated metastatic colorectal cancer patients

Project description:A phase II study of guadecitabien combined with irinotecan vs regorafenib or TAS-102 in previously treated metastatic colorectal cancer patients

2023-03-31 | GSE226221 | GEO

A trial testing TAS-102 therapy versus an alternative high-dose, intermittent scheduling for sunitinib in patients with metastatic colorectal carcinoma.

Project description:Primary objectives: The primary objective of this study is to improve progression free survival (PFS), of patients with metastatic colorectal carcinoma (mCRC) treated with high-dose sunitinib once every 2 weeks to 5 months, compared to the reported 2 months for TAS-102 monotherapy Primary endpoints: The primary objective of this study is to improve PFS of patients with stage IV colorectal carcinoma, who progressed on (or are intolerant to) 5-FU, oxaliplatin, irinotecan, anti-VEGF (and/or anti-EGFR) containing therapy, treated with high-dose sunitinib (once every 2 weeks) to 5 months, compared to 2 months for patients treated with TAS-102 monotherapy. Progression free survival is defined as the time from randomization to the date of the first documented tumor progression as determined by the investigator using RECIST 1.1 criteria or death due to any cause. PFS between patients included in the two different study arms will be compared.

| 2536629 | ecrin-mdr-crc

A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safetyand Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma

Project description:Primary objectives: The primary objective is to estimate the treatment effect on progression-free survival(PFS) of AMG 655 plus FOLFIRI or AMG 479 plus FOLFIRI relative to FOLFIRI alone when administered as a second-line treatment for subjects with metastatic colorectalcancer (mCRC) whose tumors express mutant-type Kirsten rat sarcoma virus oncogene homolog (KRAS). Primary endpoints: Progression Free Survival (PFS)PFS time is defined as the time from the date of randomization to the first observation of disease progression (as classified by modified RECIST based on the investigator assessment of radiographic scans, or clinical progression whichever occurs first,) or death due to any cause. If a subject’s disease has not progressed and the subject is alive by the analysis data cut-off date, PFS will be censored at the last date they are known to be progression-free (ie, the last evaluable disease assessment date).

| 2525121 | ecrin-mdr-crc

Estudio abierto, no aleatorizado, multicéntrico, en fase II, para evaluar la eficacia y seguridad de Bevacizumab en combinación con Capecitabina y Oxaliplatino, como primera línea de tratamiento en pacientes ancianos con adenocarcinoma colorrectal metastásico indicados para recibir tratamiento poliquimioterápico

Project description:Primary objectives: El objetivo principal del estudio es determinar el tiempo libre de progresión de la enfermedad en los pacientes ancianos sometidos al tratamiento de estudio Primary endpoints: El parámetro principal de eficacia es tiempo libre de progresión, definido como el tiempo desde el inicio del tratamiento, hasta que se objetiva enfermedad progresiva según los criterios RECIST

| 2526016 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data